Business Context and Reporting Period
Company: Prima BioMed Ltd (Note: Input metadata referenced "IMMUTEP Ltd," but the filing text identifies the registrant as Prima BioMed Ltd).
Reporting Period: Fiscal year ended June 30, 2013.
Business Overview: Prima BioMed is an Australian biotechnology company developing personalized immunocellular therapeutics for cancer. Its lead product candidate is CVac, an autologous dendritic cell-based vaccine currently in clinical trials for late-stage epithelial ovarian cancer patients in complete remission. The company has no commercial products generating revenue and operates as a development-stage enterprise.
Accounting Basis: International Financial Reporting Standards (IFRS) in Australian Dollars (A$).
Key Financial Metrics
| Metric | Fiscal 2013 (A$) | Fiscal 2012 (A$) |
|---|---|---|
| Other Income | 4,005,394 | 4,202,567 |
| Research & Development Expenses | (14,005,259) | (15,118,816) |
| Corporate Administrative Expenses | (4,851,195) | (5,977,619) |
| Net Loss | (15,225,671) | (19,940,960) |
| Loss Per Share (Basic & Diluted) | (0.0142) | (0.0192) |
| Cash and Cash Equivalents (Year End) | 22,023,143 | 16,991,716 |
| Held-to-Maturity Investments | 8,000,000 | 21,045,423 |
| Total Assets | 32,814,298 | 41,612,671 |
| Total Liabilities | 3,565,880 | 4,454,800 |
| Shareholders' Equity | 29,248,418 | 37,157,871 |
| Accumulated Deficit | (114,961,345) | (99,735,674) |
Debt: The company reported no long-term debt as of June 30, 2013. A previous convertible loan facility with SpringTree was terminated in 2011.
Liquidity: The company held A$22.0 million in cash and cash equivalents and A$8.0 million in term deposits. Management believes these resources are sufficient to fund operations for more than 12 months.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately A$4.7 million (24%) from A$19.9 million in 2012 to A$15.2 million in 2013.
- Expense Reductions:
- R&D Expenses: Decreased by A$1.1 million (7%) due to moderating enrollment in the CANVAS trial and termination of the Cripto-1 antibody program.
- Administrative Expenses: Decreased by A$1.1 million (19%) due to cost control measures and the closure of Dubai operations.
- Income Composition: Other income included A$1.6 million in cash tax rebates and grants and A$1.4 million in foreign exchange gains. Interest income decreased to A$0.9 million from A$2.7 million in the prior year due to lower cash levels on term deposits and lower interest rates.
- Cash Position: Cash and cash equivalents increased by A$5.0 million year-over-year, despite a net cash outflow from operating activities of A$16.0 million. This was supported by A$7.2 million in net cash provided by financing activities (share purchase plan and option entitlement offer) and A$12.5 million provided by investing activities (maturity of term deposits).
Guidance, Outlook, and Risks
Clinical Trial Status:
- CAN-003 (Phase 2): Top-line results announced in September 2013 indicated CVac was well-tolerated with no serious adverse events. While a T-cell response was observed, there was no observed difference in median progression-free survival between the treatment and control arms. Overall survival data is expected to be interpretable by the end of 2014.
- CANVAS (Phase 2/3): Enrollment was suspended because the trial was designed to evaluate progression-free survival as the primary endpoint, which did not show a difference in the CAN-003 study. The company is reviewing appropriate endpoints for future efficacy evaluation.
Capital Requirements: The company anticipates requiring substantial additional funds to achieve long-term goals. It does not expect to generate revenue until regulatory approval is obtained. Future funding is expected to come from public/private financings, licensing, or partnerships.
Key Risks:
- Profitability: The company has a history of operating losses and an accumulated deficit of A$115 million. It may never achieve profitability.
- Regulatory Approval: Success depends on obtaining regulatory approval for CVac, which is not guaranteed. Clinical trials may fail to demonstrate sufficient safety or efficacy.
- Manufacturing: CVac is manufactured on a patient-by-patient basis, creating logistical challenges and reliance on third-party contractors.
- PFIC Status: There is a substantial risk the company is a Passive Foreign Investment Company (PFIC), which could subject U.S. investors to adverse tax consequences.
Investor Verification Checklist
- Clinical Data Interpretation: Verify the implications of the CAN-003 results showing no difference in progression-free survival and the company's revised strategy for the suspended CANVAS trial.
- Cash Runway: Confirm the sufficiency of the A$30 million total liquid assets (cash + term deposits) against the projected burn rate for the revised clinical development plan.
- Capital Raising: Monitor upcoming capital raising activities, as the company explicitly states it will require additional financing to continue operations.
- PFIC Status: U.S. investors should consult tax advisors regarding the potential Passive Foreign Investment Company (PFIC) status and its impact on after-tax returns.
- Intellectual Property: Review the status of the terminated Biomira license agreement and the remaining patent portfolio protecting the CVac technology.